Hence, overall our results support the repositioning of propranolol as an anticancer agent in STS and suggest a possible predictive role of β-ARs in the response to docetaxel and doxorubicin-based chemotherapy, which should be evaluated through well-designed clinical trials. The gene discussed is CTBP1; the disease is telomere syndrome.